JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

Summary

This is an open-label, multicenter Phase I study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of JH021 injection in patients with advanced solid tumors. JH021 is a bispecific monoclonal antibody targeting EGFR and cMET. The study will assess JH021 in patients with advanced solid tumors for whom standard therapy is unavailable, intolerable, or no longer effective, and will provide data to support further clinical development.

Timeline

Start

2026-05-30

Primary completion

2028-05-30

Completion

2028-12-30

Drugs

Indications